Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor widely prescribed for type 2 diabetes mellitus. By blocking glucose reabsorption in the proximal renal tubule, it lowers blood glucose independently of insulin. This mechanism offers advantages across age groups, but efficacy and safety profiles shift with age-related changes in renal function, body composition, and comorbid burden. Understanding these age-specific differences helps clinicians tailor therapy for optimal outcomes.

Mechanism of Action and Clinical Role

Canagliflozin selectively inhibits SGLT2, reducing glucose reabsorption and increasing urinary glucose excretion. This insulin-independent action lowers plasma glucose without directly stimulating insulin secretion, reducing hypoglycemia risk. Beyond glycemic control, canagliflozin promotes weight loss, reduces systolic blood pressure, and improves cardiovascular and renal outcomes. Landmark trials such as CANVAS and CREDENCE have demonstrated reductions in major adverse cardiovascular events and slower progression of diabetic kidney disease, particularly in patients with established cardiovascular disease or chronic kidney disease.

However, age influences both the pharmacokinetics and pharmacodynamics of canagliflozin. Younger adults with normal renal function clear the drug predictably, while older adults often have reduced glomerular filtration rates (eGFR) that alter drug exposure. The drug is contraindicated when eGFR falls below 30 mL/min/1.73 m², and dose adjustment is recommended for moderate renal impairment (eGFR 30–59 mL/min/1.73 m²). These age-related pharmacokinetic differences directly impact prescribing decisions.

Renal Function and Drug Clearance

Age-associated decline in renal function is the most critical factor affecting canagliflozin disposition. Mean eGFR decreases by approximately 0.75–1.0 mL/min/1.73 m² per year after age 40. In patients over 75, reduced creatinine clearance increases drug half-life and area under the curve, raising the potential for accumulation. Clinical trials excluded patients with eGFR below 30, and real-world data show higher rates of adverse events in those with moderate to severe impairment. Regular monitoring of renal function is essential in older adults, especially during the first 4–6 weeks after initiation.

Body Composition and Distribution

Age-related changes in body composition—increased fat mass and decreased lean body mass—alter the volume of distribution for many drugs. While canagliflozin’s volume of distribution is relatively small (approximately 119 L), sarcopenia can influence the balance between efficacy and toxicity. Reduced muscle mass also affects creatinine-based eGFR calculations, potentially overestimating renal function in frail older adults. Clinicians should consider cystatin C-based estimation or direct measurement when dosing is uncertain.

Efficacy in Adults Aged 18–65

Glycemic and Metabolic Benefits

In younger and middle-aged adults, canagliflozin consistently reduces hemoglobin A1c (HbA1c) by 0.7% to 1.0% as monotherapy or in combination with metformin. The drug’s insulin-independent mechanism makes it effective even in patients with severe insulin resistance. Beyond glucose, weight loss of 2–4 kg over 26–52 weeks is common, accompanied by reductions in waist circumference and serum triglycerides. In patients with nonalcoholic fatty liver disease (NAFLD), canagliflozin may also reduce liver fat content, though this is not yet an FDA-approved indication.

Cardiovascular and Renal Protection

The CANVAS program showed that canagliflozin reduced the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 14% (HR 0.86, 95% CI 0.75–0.97) in adults with T2DM and high cardiovascular risk. In younger patients (under 65), the relative risk reduction was similar, but absolute event rates were lower due to fewer comorbidities. Renal benefits included a 40% reduction in progression of albuminuria and a slower decline in eGFR. Early initiation in this demographic may provide decades of cumulative protection against macro- and microvascular complications.

Adverse Events and Tolerability

Younger adults generally tolerate canagliflozin well. Genital mycotic infections occur in approximately 5–10% of women and 3–5% of men, particularly in uncircumcised males. Urinary tract infections are less common but may be more frequent in women with a history of recurrent UTIs. Osmotic diuresis symptoms—polyuria, nocturia, thirst—are dose-dependent and often subside within a few weeks. Euglycemic diabetic ketoacidosis (euDKA) is rare but can occur during illness, dehydration, or reduced carbohydrate intake. Patients should be educated on sick-day rules and symptoms of ketoacidosis.

Efficacy in Older Adults (65 Years and Older)

Glycemic Control and Frailty

In patients aged 65–74, the HbA1c-lowering effect of canagliflozin is comparable to that in younger adults, though glycemic targets may be less aggressive due to hypoglycemia concerns. For those 75 and older, glucose reduction may be slightly blunted because of age-related decline in renal function, but clinically meaningful improvements remain possible. However, limited data exist for the oldest-old (≥80). In this group, the risk of volume depletion and orthostatic hypotension is higher. Frail older adults may not benefit from the weight-loss effect; instead, unintentional weight loss can exacerbate sarcopenia and functional decline. A careful nutritional assessment is advised before initiating canagliflozin in frail patients.

Renal Safety and Monitoring

Older adults have a higher prevalence of CKD. Canagliflozin can cause an acute, reversible dip in eGFR (typically 3–5 mL/min/1.73 m²) after initiation, which is more pronounced in those with pre‑existing impairment. The CREDENCE trial demonstrated consistent renal benefits across age subgroups, but the rate of volume depletion and acute kidney injury was numerically higher in participants over 65. Guidelines recommend starting with 100 mg daily in patients with eGFR 30–59 mL/min/1.73 m² and monitoring renal function and electrolytes within 2–4 weeks. Dose reduction to 100 mg is also warranted in older adults without overt renal impairment if tolerability is a concern.

Urinary Tract and Genital Infections

Advanced age, female sex, and diuretic use increase the risk of UTIs with canagliflozin. Observational studies report a higher incidence of complicated UTIs and pyelonephritis in older women, although absolute risk remains low. Preventive strategies include adequate hydration, prompt treatment of any UTI symptoms, and avoidance in patients with recurrent complicated UTIs. Genital mycotic infections are also more common in older women, particularly those with vaginal atrophy. Topical antifungal therapy is usually effective, but clinicians should consider discontinuation if infections recur frequently.

Cardiovascular Outcomes in Older Adults

Subgroup analyses from CANVAS and CREDENCE show that the cardiovascular benefits of canagliflozin are preserved in older adults. In the CANVAS program, the hazard ratio for the primary composite endpoint was 0.86 (0.76–0.97) in those under 65 and 0.87 (0.74–1.01) in those 65 and older. For hospitalization for heart failure, the benefit appeared to be even more pronounced in older patients. However, older adults had higher rates of adverse events leading to discontinuation, primarily due to volume depletion and renal events. These findings underscore the importance of careful volume status assessment and baseline renal function evaluation before prescribing.

Special Considerations for the Elderly

Polypharmacy and Drug Interactions

Older adults often take multiple medications for hypertension, dyslipidemia, and pain. Canagliflozin has few drug interactions, but co‑administration with loop diuretics or angiotensin‑converting enzyme inhibitors increases the risk of intravascular volume depletion and hypotension. When starting canagliflozin, clinicians may need to temporarily reduce or hold diuretic doses. Additionally, canagliflozin may increase serum lithium levels by affecting renal tubular reabsorption; lithium concentrations should be monitored within the first week and after dose changes. No significant interactions with statins, antiplatelet agents, or anticoagulants have been reported.

Hypoglycemia Risk

Canagliflozin alone has a low intrinsic risk of hypoglycemia, but combining it with sulfonylureas or insulin raises that risk. In older adults with impaired counter‑regulatory responses to hypoglycemia, even mild episodes can precipitate falls, confusion, or cardiac events. The American Diabetes Association recommends reducing the dose of sulfonylureas or insulin by 10–20% when adding an SGLT2 inhibitor. Continuous glucose monitoring can be beneficial for high‑risk patients, especially those with a history of recurrent hypoglycemia or cognitive impairment.

Perioperative and Sick-Day Management

Euglycemic diabetic ketoacidosis (euDKA) is a rare but serious adverse effect of SGLT2 inhibitors, often triggered by stress, surgery, infection, or fasting. In older adults, reduced renal function and delayed symptom recognition can increase the risk. Guidelines recommend discontinuing canagliflozin at least 3–4 days before elective surgery and resuming only after the patient is clinically stable with adequate oral intake. Clear sick‑day rules—stopping the drug during vomiting, diarrhea, or illness with reduced food intake—should be communicated to patients and caregivers.

Comparative Analysis: Younger vs. Older Adults

Cardiovascular Protection

Meta‑analyses of SGLT2 inhibitors show a consistent reduction in the composite of cardiovascular death, nonfatal MI, and nonfatal stroke (HR 0.88, 95% CI 0.81–0.95). In age‑stratified analyses, the benefit was observed in both younger and older groups, but absolute risk reduction was larger in older adults due to higher baseline risk. For example, in CANVAS, the 3‑year composite event rate among placebo‑treated patients aged ≥65 was 12.2% versus 5.8% in those aged <65. The number needed to treat for one year to prevent one event was approximately 60 for younger patients and 30 for older patients.

Renal Outcomes

In CREDENCE, canagliflozin reduced the primary renal composite outcome—doubling of creatinine, end‑stage kidney disease, or renal death—by 34% (HR 0.66, 0.53–0.81). This benefit was consistent across age subgroups. However, older patients experienced higher rates of adverse events leading to discontinuation, particularly volume depletion and acute kidney injury. This reinforces the need for baseline eGFR and albuminuria assessment, careful monitoring, and individualized treatment targets. In very elderly patients with advanced CKD (eGFR <30), the risks may outweigh benefits, and alternative agents should be considered.

Clinical Practice Recommendations

  • Obtain baseline eGFR and urine albumin-to-creatinine ratio. Canagliflozin is contraindicated when eGFR <30 mL/min/1.73 m². For eGFR 30–59, start with 100 mg once daily.
  • Assess volume status and fall risk. In older adults, evaluate for orthostatic hypotension, edema, and concurrent use of diuretics. Consider temporarily reducing diuretic doses upon initiation.
  • Educate on genital and urinary hygiene. Teach patients and caregivers to recognize symptoms of infections and seek prompt treatment. Avoid in those with recurrent complicated UTIs.
  • Monitor weight and nutritional status. In frail or malnourished older adults, assess baseline body weight and lean body mass. Implement dietary support if needed to prevent excessive weight loss.
  • Implement sick-day rules and perioperative guidance. Provide written instructions to stop the drug during illnesses that reduce oral intake and discontinue 3–4 days before elective surgery.
  • Consider deprescribing in limited life expectancy. In very elderly patients with multiple advanced comorbidities, the incremental benefit of further glycemic lowering is often marginal. Shared decision‑making should guide therapy intensity.

Emerging Evidence and Future Directions

Heart Failure with Preserved Ejection Fraction

Although the DELIVER and EMPEROR‑Preserved trials studied dapagliflozin and empagliflozin, respectively, the SGLT2 inhibitor class effect likely extends to canagliflozin. A post‑hoc analysis of CANVAS showed a 33% reduction in hospitalization for heart failure, with similar benefit across age groups. Ongoing real‑world studies are evaluating canagliflozin in older, multimorbid populations, including those with heart failure and preserved ejection fraction.

Real-World Evidence in Older Adults

Large claims‑database studies show that canagliflozin is increasingly prescribed in patients aged 75 and older. These studies confirm a safety profile similar to that in clinical trials, but with higher absolute rates of volume depletion and acute kidney injury. Real‑world evidence also suggests that the cardiovascular benefits are maintained in routine clinical practice. Future pragmatic trials should include a broader representation of older adults, including those with frailty, cognitive impairment, and polypharmacy, to refine prescribing recommendations.

Guideline Updates

The American Diabetes Association Standards of Care (2024) recommend SGLT2 inhibitors as first‑line therapy for patients with T2DM and established cardiovascular disease, heart failure, or CKD. Age alone is not a contraindication, but careful patient selection and monitoring are emphasized. The National Kidney Foundation guidelines provide specific renal‑oriented recommendations for SGLT2 inhibitor use.

Conclusion

Canagliflozin is a potent SGLT2 inhibitor that offers robust glycemic control, cardiovascular protection, and renal benefits across adult age groups. In younger adults (18–65), it is well tolerated and provides long‑term advantages with a favorable side effect profile. In older adults (≥65), especially those aged 75 and above, the same benefits persist, but careful monitoring of renal function, volume status, and nutritional health is essential to mitigate higher rates of adverse events. Successful use of canagliflozin depends on personalized prescribing: appropriate dose adjustments based on renal function, patient education on infection prevention and sick‑day management, and systematic assessment of frailty and comorbidities. With this approach, canagliflozin remains a valuable tool for diabetes management across the entire adult lifespan.

For further reading on SGLT2 inhibitor prescribing in older adults, refer to the FDA safety communication on SGLT2 inhibitors and the National Kidney Foundation clinical practice guidelines. Additionally, the American Diabetes Association 2024 Standards of Care offer detailed recommendations for age‑specific pharmacotherapy. A comprehensive review of SGLT2 inhibitor use in the elderly is available in this 2023 meta‑analysis published in Diabetes Care.